A detailed history of Two Sigma Investments, LP transactions in Infla Rx N.V. stock. As of the latest transaction made, Two Sigma Investments, LP holds 24,013 shares of IFRX stock, worth $53,789. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,013
Previous 51,541 53.41%
Holding current value
$53,789
Previous $89,000 59.55%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.34 - $1.73 $36,887 - $47,623
-27,528 Reduced 53.41%
24,013 $36,000
Q2 2024

Aug 14, 2024

SELL
$1.18 - $1.74 $59,795 - $88,172
-50,674 Reduced 49.58%
51,541 $89,000
Q1 2024

May 15, 2024

SELL
$1.47 - $2.03 $53,155 - $73,404
-36,160 Reduced 26.13%
102,215 $157,000
Q4 2023

Feb 14, 2024

BUY
$1.25 - $2.75 $157,437 - $346,362
125,950 Added 1013.68%
138,375 $225,000
Q3 2023

Nov 14, 2023

BUY
$2.66 - $4.33 $33,050 - $53,800
12,425 New
12,425 $37,000
Q2 2022

Aug 15, 2022

SELL
$0.78 - $1.9 $38,396 - $93,529
-49,226 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$1.83 - $4.48 $20,025 - $49,024
-10,943 Reduced 18.19%
49,226 $90,000
Q4 2021

Feb 14, 2022

BUY
$2.35 - $5.58 $115,382 - $273,972
49,099 Added 443.53%
60,169 $286,000
Q3 2021

Nov 15, 2021

BUY
$2.25 - $3.03 $24,907 - $33,542
11,070 New
11,070 $29,000
Q3 2020

Nov 16, 2020

SELL
$3.7 - $5.47 $246,553 - $364,498
-66,636 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$4.59 - $8.96 $305,859 - $597,058
66,636 New
66,636 $306,000
Q4 2019

Feb 14, 2020

SELL
$2.2 - $4.54 $164,472 - $339,410
-74,760 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$2.47 - $3.51 $75,804 - $107,721
30,690 Added 69.64%
74,760 $185,000
Q2 2019

Aug 14, 2019

BUY
$3.06 - $51.61 $134,854 - $2.27 Million
44,070 New
44,070 $139,000

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $99M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.